Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

mRNA vaccine

- PMLiVE

EMA’s emergency task force backs bivalent COVID-19 vaccines for primary vaccination

National authorities may decide to use the vaccines in their primary vaccination campaigns

- PMLiVE

Pfizer and Clear Creek Bio partner on COVID-19 antiviral research programme

The companies will identify a papain-like protease candidate to progress into the clinic

- PMLiVE

Pfizer/BioNTech submit FDA application for BA.4/BA.5 COVID-19 vaccine in children under five

The vaccine is already authorised as a booster for ages five years and older in the US and EU

- PMLiVE

Kinarus’ KIN001 shows strong antiviral activity against BA.2 and BA.5 Omicron subvariants

The phase 2 trial of KIN001 in ambulatory COVID-19 patients is actively recruiting

- PMLiVE

Pfizer and Roivant form new company to develop inflammatory disease drug

RVT-3101 is currently being evaluated in a global phase 2b study for ulcerative colitis

- PMLiVE

Pfizer and Valneva report six-month antibody persistence data for Lyme disease vaccine

VLA15 is the only Lyme disease vaccine candidate currently in clinical development

- PMLiVE

BioNTech and Ryvu partner to develop immuno-modulatory small molecule candidates

The focus will be on immune modulation within oncology and potentially other disease areas

- PMLiVE

National trial to rapidly find treatments for severe flu this winter launched in UK

REMAP-CAP will test multiple treatments at the same time in thousands of people

- PMLiVE

mRNA technology for universal flu vaccine shows early promise in US study

The evolving nature of influenza viruses requires frequent reformulation of vaccines

Can Cinderella save us?

UK government launches consultation on silent AMR pandemic

The consultation will call upon the latest data from experts on antimicrobial resistance

- PMLiVE

Moderna’s bivalent Omicron-targeting boosters show superiority to original COVID-19 vaccine

Both boosters produced a better immune response against Omicron BA.4/BA.5 subvariants

- PMLiVE

NICE publishes draft guidance recommending three COVID-19 treatments

Five treatments have not been recommended for use, with the organisation citing cost-effectiveness concerns

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links